EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Anna Dorothea Wagner*, Heike Grabsch, Murielle Mauer, Sandrine Marreaud, Carmela Caballero, Peter Thuss-Patience, Lothar Mueller, Annelie Elme, Markus Hermann Moehler, Uwe Martens, Yoon-Koo Kang, Sun Young Rha, Annemieke Cats, Masanori Tokunaga, Florian Lordick

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number494
Number of pages9
JournalBMC Cancer
Volume19
DOIs
Publication statusPublished - 24 May 2019

Keywords

  • Gastric cancer
  • Gastro-esophageal junction cancer
  • Perioperative chemotherapy
  • Trastuzumab
  • Pertuzumab
  • HER2
  • NEOADJUVANT CHEMOTHERAPY
  • BREAST-CANCER
  • OPEN-LABEL
  • CAPECITABINE
  • OXALIPLATIN
  • REGRESSION
  • DOCETAXEL
  • SURGERY

Cite this